Divalproex Sodium Tablet, Delayed Release
Product Images NDC 62756-796

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 62756-796). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

This appears to be a figure displaying the results of two studies, Study 1 and Study 2, involving PBO and DVPX treatments. The abbreviations YMRS and MRS may refer to different scales or measures used in assessing the efficacy of these treatments, but further context is needed to understand the meaning of the data presented in this figure.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

The text seems to be a graph, showing different percentages and values of reduction in CPS rate, improvement, no change, and worsening among patients. The graph includes two lines, one labeled "DVPX" and the other "Placebo." The meaning of the abbreviations "CPS" and "DVPX" is not clear from the provided text, but the graph appears to be related to medical or clinical research.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

The text appears to be a visual aid of some sort, likely a graph. It shows the mean 4-week migraine rates for two different treatments: Placebo and DVPX. There are two studies represented in the graph (Study 1 and Study 2) and there are possibly two different forms of DVPX being compared (DVPX' and DVPX*). Without the actual graph, it is difficult to provide further detail or interpretation.*

FDA Label Image

Spl-divalproex-label-125mg (Spl Divalproex Label 125mg)

FDA Label Image

Spl-divalproex-label-250mg (Spl Divalproex Label 250mg)

This text appears to be a description of a medication called Divalproex Sodium, which is an enteric-coated, delayed-release tablet containing 250 mg of Valproic Acid. The tablets are orange colored and are imprinted with the numbers 797 on one side and blanks on the other to help with identification. The information specifies that the medication is only available with a prescription and provides instructions for storage and dispensation. A medication guide is available to be given to each patient when prescribed, and the text provides a manufacturer and distributor address.*

FDA Label Image

Spl-divalproex-label-500mg (Spl Divalproex Label 500mg)

Each enteric-coated delayed-release tablet contains 500mg of Divalproex sodium, USP equivalent to valproic acid. The tablet is pink colored, plain on one side and bears ‘798" imprinted with black ink on the other side for easy identification. Please refer to the package insert for the recommended dosage. The medication should be stored at a temperature between 20°C-25°C (68°F-77°F) with minor excursions permitted to 15°C-30°C (59°F-86°F). Pharmacist must dispense the medication guide to every patient. Do not take medication if the seal over the bottle is open or missing. The medication can be obtained from Sun Pharmaceutical Industries, Inc. The NDC is 62756-798-83.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.